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PCardiac Magnetic Resonance
oes Subclinical Hypothyroidism
ffect Cardiac Pump Performance?
vidence From a Magnetic Resonance Imaging Study
ndrea Ripoli, PHD,* Alessandro Pingitore, MD, PHD,* Brunella Favilli, MSC,* Antonio Bottoni, MD,*
tefano Turchi, BSC,* Nael F. Osman, PHD,† Daniele De Marchi, RT,* Massimo Lombardi, MD,*
ntonio L’Abbate, MD,‡ Giorgio Iervasi, MD*
isa, Italy and Baltimore, Maryland
OBJECTIVES We sought to assess the effects of subclinical hypothyroidism (SHT) on the cardiac volumes
and function.
BACKGROUND The cardiovascular system is one of the principal targets of thyroid hormones. Subclinical
hypothyroidism is a common disorder that may represent “early” thyroid failure.
METHODS Thyroid profile was evaluated in 30 females with SHT and 20 matched control subjects. Left
ventricular end-diastolic volume (EDV) and end-systolic volume (ESV), stroke volume (SV),
cardiac index (CI), and systemic vascular resistance (SVR) were calculated by cardiac
magnetic resonance (CMR). Regional greatest systolic lengthening (E1) and greatest systolic
shortening (E2) were calculated by tagging CMR.
RESULTS EDV was lower in SHT than in controls (64.3 8.7 ml/m2 vs. 81.4 11.3 ml/m2, p 0.001),
as well as SVR (38.9 7.5 ml/m2 vs. 52.5 6.1 ml/m2, p 0.001) and CI (2.6 0.5 l/[min·m2]
vs. 3.7 0.4 l/[min·m2], p 0.001). Systemic vascular resistance was higher in SHT (12.5 2.5
mm Hg·min/[l·m2] vs. 8.6 1.1 mm Hg·min/[l·m2], p 0.003). The E1 was higher in controls
than in SHT at the basal (p 0.007), equatorial (p 0.05), and apical (p 0.008) levels, as well
as E2 at the equatorial (p 0.001) and apical (p 0.001) levels. All parameters normalized after
replacement therapy. A negative correlation between TSH and EDV (p  0.001), SV (p 
0.001), CI (p 0.001), and E1 at the apical level (p 0.001) and a positive correlation between
TSH and SVR (p  0.001) and E2 at the apical level (p  0.001) were found.
CONCLUSIONS Subclinical hypothyroidism significantly decreased cardiac preload, whereas it increased
afterload with a consequent reduction in SV and cardiac output. Replacement therapy fully
normalized the hemodynamic alterations. (J Am Coll Cardiol 2005;45:439–45) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.044the American College of Cardiology Foundation
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mhe cardiovascular system is one of the principal targets of
hyroid hormones (1). The cellular mechanisms by which
hyroid hormones act on systolic and diastolic cardiac
unction are complex and at different levels. Thyroid hor-
ones modulate the expression and function of several
nzymes and proteins involved in the cardiac performance,
uch as sarcoplasmic reticulum Ca ATPase (SERCA II),
a/K ATPase, and alpha/beta-myosin heavy chains (2).
he effect of altered thyroid function is well demonstrated
n clinical practice by the typical cardiovascular alterations
bserved in patients with either overt hyperthyroidism or
ypothyroidism (3–5). However, the cardiac effect of subtle
hyroid dysfunction is less clear and documented. Subclin-
cal (mild) hypothyroidism (SHT) is a very common disor-
er that may represent asymptomatic “mild” thyroid failure
n which substitutive treatment with synthetic thyroid
ormones is still controversial (6,7). The prevalence of SHT
anges between 2% and 20% of the adult population, and
From the *Institute of Clinical Physiology, C.N.R., Pisa, Italy; †Johns Hopkins
niversity, Baltimore, Maryland; and ‡Scuola Superiore S. Anna and Institute of
linical Physiology, C.N.R., Pisa, Italy.(
Manuscript received March 2, 2004; revised manuscript received October 1, 2004,
ccepted October 18, 2004.omen are predominantly affected (7–9). Subclinical hypo-
hyroidism is characterized by an increased serum thyro-
ropin (thyroid-stimulating hormone [TSH]) concentration
n the presence of normal values of free thyroxine (FT4) and
f biologically active free tri-iodothyronine (FT3) (10).
lthough thyroid hormones are within the normal range,
ome cardiovascular effects have been documented in SHT
s impaired diastolic relaxation and reduced exercise capa-
ility (11,12); both of these alterations are reversible with
ynthetic thyroid hormone replacement (13,14).
Whether SHT also affects left ventricular (LV) volumes
nd systolic function at rest remains to be established (7,15).
Cardiac magnetic resonance (CMR) is considered the
old standard for evaluating cardiac volumes and function
16). Gradient echo sequences provide a naturally high level
f contrast between intracavitary blood and myocardium,
hus allowing an accurate and reproducible determination of
V volumes and mass and calculation of SV and ejection
raction. In this context, additional information can also be
rawn from application of the more recent CMR tagging
nalysis, which represents a noninvasive highly accurate
ethod for direct quantification of regional systolic function17).
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Subclinical Hypothyroidism and Cardiac Function February 1, 2005:439–45The aim of the present study was to assess the cardiac
orphology and ventricular systolic function in patients
ith SHT before and after substitutive treatment with
ynthetic thyroid hormone.
ETHODS
atients. Fifty female patients were enrolled in the study.
f these, 30 (mean age 41.2  6.9 years) had the first
iagnosis of SHT (i.e., 4.00  TSH  15 IU/ml,
onfirmed by two different serum determination in one
onth) in the presence of both FT3 and FT4 in the normal
ange, due to autoimmune thyroiditis; the remaining 20
mean age 38.4  9.4 years) with absent thyroid autoanti-
odies, normal thyroid function (i.e., normal FT4, FT3, and
SH), and normal ultrasound thyroid pattern served as
ontrols. All patients were free from any other concomitant
isorder and from any treatment for at least three months.
ll patients and controls underwent thyroid hormone sam-
ling and CMR in the same day. In 26 patients with SHT,
MR was repeated after reversal of SHT by synthetic
hyroid hormone replacement therapy, as assessed by nor-
alization of TSH (obtained values ranging between 0.4
nd 2.5 IU/ml). The remaining four patients refused to
ndergo CMR for a second time (after treatment). The time
ange from the first to the second CMR was 70 to 138 days
median 86 days).
hyroid hormones assay. The thyroid function profile was
etermined by measuring FT4, FT3, and TSH through a
ully automated AIA system, as previously reported (18).
he reference intervals for our laboratory were: FT3 2.0 to
.2 pg/ml (3.2 to 6.5 pmol/l), FT4 7.1 to 18.5 pg/ml (9.2 to
4.0 pmol/l), and TSH 0.30 to 3.80 IU/ml.
he CMR technique. Cardiac magnetic resonance was
erformed on a whole-body magnetic resonance imaging
canner (Signa Cvi, GE), operating at 1.5-T using a surface
hased-array coil. The CMR acquisition was performed
ccording to a standardized protocol. Cardiac images were
btained using breath-hold segmented gradient echo FI-
STA (Fast Imaging Employing Steady State Acquisition)
Abbreviations and Acronyms
CI  cardiac index
CMR  cardiac magnetic resonance
DWT  diastolic wall thickness
E1  greatest systolic lengthening
E2  greatest systolic shortening
EDV  end-diastolic volume
ESV  end-systolic volume
FT3  free tri-iodothyronine
FT4  free thyroxine
LV  left ventricular
SHT  subclinical hypothyroidism
SV  stroke volume
SVR  systemic vascular resistance
TSH  thyroid-stimulating hormonelectrocardiographically triggered sequences. The echo time Das 1.7 ms; repetition time 4.0 ms; slice thickness 8 to 10
m with no interslice gap; field of view from 320 to 380
m; data matrix size 256 224; phase of field of view 0.75;
rigger delay was minimum; and views per segment 8 to 12
ccording to heart rate; flip angle 45°. Thirty cine frames
ere obtained both in four-chamber view and two-chamber
iews to measure LV dimensions. On the four-chamber
iew slice, the LV was covered from the base to apex, with
stack of slices in the true short axis. The basal short-axis
lice was positioned just forward of the atrioventricular ring,
nd all subsequent breath-hold slices were acquired toward
he apex. The tagging pulse sequence consisted of nonse-
ective radiofrequency pulses separated by spatial modula-
ion of magnetization-encoding gradients to achieve tag
eparation of 7 mm (19). Three base-to-apex short-axis
ections were prescribed (basal, equatorial, and apical re-
ion). Two sets of identical short-axis views were acquired,
ith the second set rotated by 90°; in this way, we imaged
he three slices within three breath-holds (about 20 s each).
he number of views per phase was optimized on the basis
f the patient’s heart rate.
ardiac magnetic resonance data analysis. Left ventricle
ontours were drawn in end-diastolic and end-systolic
hort-axis frames using a commercial post-processing pro-
ram (Mass Analysis, Leiden, The Netherlands) on an
ndependent Sun-pare Station. Left ventricular end-
iastolic volume (EDV) and end-systolic volume (ESV)
ere measured by manual planimetry and subsequent mul-
iplication with slice thickness. Final LV volumes were
alculated by simple addition of the individual slice volumes
n the stack of contiguous slices for the entire LV. The
ndexed volumes of the LV were obtained by dividing EDV
nd ESV by the body surface area. Left ventricular mass
ndex (g/m2) was calculated by multiplying the difference
etween epicardial and endocardial end-diastolic indexed
olumes by the density of myocardial tissue (1.05 g/ml).
oth EDV and ESV were used to calculate LV indexed
troke volume (SV, ml/m2) and ejection fraction. Cardiac
ndex (CI, ml/[min·m2]) was obtained as the product of SV
nd heart rate. Systemic vascular resistance (SVR, mm
g·min/l·m2) was calculated as mean arterial blood pressure
ivided by cardiac output: the obtained value was indexed by
ody surface area. The LV was divided into four walls
septum, anterior, lateral, and inferior) and 12 segments,
ncluding four basal, equatorial, and apical segments. Dia-
tolic wall thickness (DWT) of the 12 LV segments was
alculated, and the index of this DWT was obtained by
ividing the sum of the individual segment values by the
umber of the 12 LV segments. Wall motion of the same 12
V segments was graded semiquantitatively as 1  normal;
 hypokinetic; 3  akinetic; and 4  dyskinetic. The
nalysis of tagged cardiac images was performed using
armonic Phase (HARP) CMR, obtaining a fast and
ccurate assessment of two-dimensional strain fields (20).
agged analysis was performed at the same segments of the
WT and wall motion. For each segment, the two-
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February 1, 2005:439–45 Subclinical Hypothyroidism and Cardiac Functionimensional strain field was assessed by computing the
reatest systolic lengthening (E1, %), corresponding to wall
hickening, and the greatest systolic shortening (E2, %),
hich is in the circumferential direction, as well as the
ngular deviation of E1 from the radial direction. The
ensitivity of the HARP method to small changes in
yocardial strain and its potential application in clinical
ardiology have already been described (21). Operators were
linded as to the patient group during the analysis of the LV
arameters.
tatistical analysis. Data are expressed as the mean value 
D. The two-tailed independent samples t test was used to
ompare the results of the control and SHT groups. The
wo-tailed paired samples t test was used to compare the SHT
roup before and after therapy. The strength of correlation
etween variables was assessed by Pearson coefficient (R). A p
alue 0.05 was considered statistically significant.
ESULTS
linical and hormonal characteristics. The demographic,
linical, and thyroid functional data are reported in Tables 1
nd 2. There were no significant differences in age, body
urface area, diastolic and mean blood pressure, and heart
ate between the SHT and control groups. In the 26
able 1. Clinical and Thyroid Profile in Control Subjects and
atients With Subclinical Hypothyroidism Before Therapy
All Patients Enrolled)
Controls
(n  20)
SHT Patients
(n  30) p Value
ge (yrs) 38.4  9.4 41.2  6.9 NS
SA (m2) 1.65  0.8 1.73  0.15 NS
R (beats/min) 71.4  7.8 67.5  8.7 NS
BP (mm Hg) 111.8  13.7 124.4  14.3 NS
BP (mm Hg) 72.6  5.9 74.6  8.1 NS
BP (mm Hg) 84.8  7.1 92.5  10.4 NS
SH (IU/ml) 2.31  0.6 8.7  3.7 0.001
T3 (pg/ml) 3.4  0.4 3.2  0.5 NS
T4 (pg/ml) 11.8  1.5 11.4  3.1 NS
ata are presented as the mean value  SD.
BSA  body surface area; DBP  diastolic blood pressure; FT3  free
ri-iodothyronine; FT4  free thyroxine; HR  heart rate; MBP  mean blood
ressure; NS  not significant; SBP  systolic blood pressure; SHT  subclinical
ypothyroidism.
able 2. Clinical and Thyroid Profile in Subclinical
ypothyroidism Patients Before and After Therapy
SHT Before
Therapy
(n  30)
SHT After
Therapy
(n  26) p Value
R (beats/min) 66.5  7.1 67.1  7.2 NS
BP (mm Hg) 122.6  16 117.3  16.1 NS
BP (mm Hg) 75.5  7.6 73.6  11.7 NS
BP (mm Hg) 91.8  9.4 88.1  12.3 NS
SH (IU/ml) 8.3  3.5 0.88  0.5 0.001
T3 (pg/ml) 3.2  0.6 4.3  0.7 NS
T4 (pg/ml) 11.1  2.9 18.8  5.3 0.01ata are presented as the mean value  SD.
Abbreviations as in Table 1.
tubjects reevaluated after treatment, the mean value of TSH
as significantly lower and that of FT4 was higher than the
orresponding values before therapy. Values of clinical and
hyroid functional variables in the 26 treated patients with
HT were not significantly different from those of controls.
olumes and global function of the LV. Indexed systolic
nd diastolic volumes, as well as the indexes of global LV
unction in SHT before therapy and in control group, are
eported in Table 3. The SHT group differed for EDV, SV,
I, and SVR, as compared with the control group. Cardiac
arameters measured before and after thyroid replacement
herapy in the SHT group are reported in Table 4. The
DV, SV, ejection fraction, and CI increased and SVR
ecreased after treatment. After treatment, no difference
as found relative to the control group. By considering all
ubjects as a whole (control and SHT groups before and
fter treatment, Fig. 1), there was a significant correlation
etween TSH values and CI (R0.60, p 0.001), SVR
R  0.60, p  0.001), SV (R  0.58, p  0.001), EDV
R0.58, p 0.001), and ejection fraction (R0.50,
 0.001).
egional systolic function of the LV. Wall motion was
ormal in all segments of both the control and SHT groups.
1 was significantly higher in normal subjects than in SHT
able 3. Morphologic and Global Functional Parameters of the
eft Ventricle in Control Subjects and Subclinical
ypothyroidism Patients Before Therapy (All Patients Enrolled)
Controls
(n  20)
SHT Patients
(n  30) p Value
DV (ml/m2) 81.4  11.3 64.3  8.7 0.001
SV (ml/m2) 31.5  8.3 29.1  5.5 NS
V (ml/m2) 52.5  6.1 38.9  7.5 0.001
I (l/[min·m2]) 3.7  0.4 2.6  0.5 0.001
F (%) 65  5.5 61.0  6.4 NS
VR (mm Hg·min/[l/m2]) 8.6  1.1 12.5  2.5 0.003
VM (r/m2) 81.0  8.0 84  16.3 NS
WT (mm) 6.3  0.4 6.0  0.6 NS
ata are presented as the mean value  SD.
CI  cardiac index; DWT  diastolic wall thickness; EDV  end-diastolic
olume; EF  ejection fraction; ESV  end-systolic volume; LVM  left ventricular
ass; NS not significant; SHT subclinical hypothyroidism; SV stroke volume;
VR  systemic vascular resistance.
able 4. Morphologic and Global Functional Parameters of the
eft Ventricle in the Subclinical Hypothyroidism Patients
efore and After Therapy
SHT Before
Therapy
(n  30)
SHT After
Therapy*
(n  26) p Value
DV (ml/m2) 64.8  8.3 78.0  11.5 0.001
SV (ml/m2) 28.9  6.0 29.0  6.5 NS
V (ml/m2) 39.1  6.5 48.7  8.5 0.001
I (l/[min·m2]) 2.6  0.3 3.2  0.5 0.002
F (%) 59.7  6.4 65.5  7.0 0.001
VR (mm Hg·min/[l/m2]) 12.5  2.7 9.1  1.4 0.001
VM (g/m2) 73.8  15.9 75.3  16.1 NS
WT (mm) 5.9  0.6 6.0  0.6 NS
There are no significant differences between controls and SHT patients after
reatment. Data are presented as the mean value  SD.
Abbreviations as in Table 3.
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cantly higher, in absolute value, in normal subjects only at the
quatorial and apical levels; the alpha value was not signifi-
antly different in SHT patients as compared with normal
ubjects in each of the three levels considered (Fig. 2). Con-
idering controls and SHT patients (both before and after
reatment) as a whole, there was a significant correlation
etween TSH values and both E1 (R  0.70, p  0.001)
nd E2 (R  0.59, p  0.001) at the apical level (Fig. 1), and
1 only at the equatorial level (R0.42, p 0.001). When
HT patients were evaluated before and after therapy, a
ignificant increase was observed in E1 at the equatorial and
pical levels, and in E2, in absolute value, at the apical level
nly; the alpha value remained unchanged before and after
reatment (Fig. 3).
ISCUSSION
he main finding of the present study is that patients with
HT showed reduced EDV (decreased preload) and in-
reased systemic vascular resistance (increased afterload),
igure 1. Scatterplots showing the relationship between thyroid-stimulating
ndex (CI), systemic vascular resistance (SVR), and apical greatest systolic
ubclinical hypothyroidism (SHT) patients before thyroid replacement th
riangles  control group.eading to impairment of cardiac pump performance, as sompared with normal subjects. The result of pump failure
as the reduction of SV, as well as cardiac output, because
eart rate was unaffected. All hemodynamic alterations
eversed to normal after thyroid hormone replacement
herapy. Moreover, a relatively good relationship was found
etween TSH, as the best biochemical marker of whole-
ody thyroid hypofunction, and the parameters of systolic
V performance. The observed scatter about the line of
greement may be at least in part ascribed to the relatively
ow sensitivity of TSH as a marker of the severity of
ypothyroidism in the peripheral target tissues (22). To our
nowledge, this is the first comprehensive study that em-
loyed the CMR and tagging CMR techniques to evaluate
ardiac morphology and function in patients with mild
ypothyroidism; this makes a comparison with previous
eports in the same field difficult. Only the CMR study,
one in a severe and acute model of hypothyroidism
econdary to total thyroidectomy, gave, at least in part,
omparable results (23). On the other hand, the few
chocardiographic studies performed in SHT (13,24–26)
one (TSH) and end-diastolic volume (EDV), stroke volume (SV), cardiac
hening (E1) and apical greatest systolic shortening (E2). Open circles 
; filled circles  SHT patients after thyroid replacement therapy; openhorm
lengthowing diastolic relaxation impairment and reduced exer-
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February 1, 2005:439–45 Subclinical Hypothyroidism and Cardiac Functionise tolerance remain largely inconclusive as far as resting
V systolic function is concerned (7). Apart from possible
ifferences in patient selection, different and somewhat
ontrasting data might be ascribed to the relatively poor
ccuracy of the method utilized for the assessment of
ystolic cardiac function (7). To overcome all of these
rawbacks, we enrolled a selected group of patients of
elatively young age with SHT, free from previous and/or
oncomitant additional disease and from medical treatment.
he technique we adopted is considered the gold standard
or the noninvasive assessment of cardiac performance (i.e.,
or evaluating both cardiac volumes and indexes of global
V function) (16). The principal advantages of the CMR
echnique are the high image resolution, allowing accurate
efinition of the endocardial and epicardial borders, and the
hree-dimensional approach, allowing direct volume recon-
truction of the LV without any geometric assumption (16).
mportantly, beside the clearly documented alteration in the
lobal LV volumes and function, a significant difference in
egional systolic performance has been shown in patients
ith SHT by the use of the more sophisticated tagging
MR analysis. The accuracy of this technique in the
valuation of regional intramyocardial contractility is
perator-independent and relies on the ability to trace the
ame portion of the myocardium during the cardiac cycle,
aking the evaluation of this parameter accurate to the level
f sonomicrometers—the invasive gold standard method
igure 2. Histograms showing the values of the tagging parameters in the
lfa  angular deviation of greatest systolic lengthening (E1); E2  grea27). In this study, the analysis of regional strains allowed tccurate information on the regional nonuniformity of the
V, with numerical values in agreement with previously
eported studies in normal adult hearts (20,28,29). We
ound that wall thickening (E1) and circumferential short-
ning (E2) were significantly lower in patients with SHT as
ompared with controls. Moreover, E1 and E2 differences
etween normal subjects and SHT patients, as well as
etween SHT patients before and after hormonal therapy,
ppeared to be more evident and significant when moving
rom the base to apex of the ventricle. On the other hand,
he angular deviation did not differ in SHT patients and
ormal subjects; this result is in agreement with the nature
f this parameter, sensitive only to dyskinetic motions, and
ith the typology of subjects enrolled in the study, each
ith “normal” ventricular function.
The intrinsic mechanisms responsible for reduced LV
DV and for its normalization in SHT after thyroid
ormone replacement therapy cannot be fully explained by
he present data, per se. It seems very unlikely that the
bserved LV volume changes before and after therapy were
elated to blood volume variations, documented only in
vert hypothyroidism but not in SHT (30). A hypothetical
echanism might be the redistribution of blood volume
ith subtraction of circulating blood from the systemic
irculation, although the nature of such mechanism remains
bscure. Conversely, the increase in systemic vascular resis-
ance is in agreement with the known vasodilatory effect of
rol group and subclinical hypothyroidism (SHT) group before treatment.
ystolic shortening.hyroid hormone. The association of reduced preload with
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Subclinical Hypothyroidism and Cardiac Function February 1, 2005:439–45ncreased afterload, observed in SHT in the present study, is
n line with the systemic effect of the thyroid hormone, by
hich central and peripheral effects act synergistically to
mprove systolic performance (31–34). Changes in preload
nd afterload are sufficient reason to explain the decrease in
ystolic pump performance observed in SHT patients,
ithout the need to invoke simultaneous impairment in
yocardial inotropic function. Accordingly, for similar val-
es of ESV, systolic arterial pressure did not differ among
atient subgroups and the control group, suggesting a
imilar degree of contractility. On the basis of this consid-
ration, regional changes observed in E1 and E2 might be
nterpreted as the result of parallel changes in cardiac
oading conditions.
tudy limitations. The relatively small size of the studied
atient population could represent a potential drawback;
owever, the relevant cost of CMR limits its routine use.
oreover, the high resolution and reproducibility of the
MR imaging technique optimizes the likelihood of de-
ecting the small differences (16) that we observed among
ntreated and treated SHT and control groups. Notwith-
tanding the high incidence of SHT (7–9), we enrolled a
estricted but highly selected group of patients by including
nly those with SHT, without any other concomitant
isorders, and free from any treatment.
onclusions. The present study demonstrates that there
re measurable differences in cardiac volumes and systolic
igure 3. Histograms showing the values of the tagging parameters in the
ngular deviation of greatest systolic lengthening (E1); E2  greatest systerformance in patients with SHT; all these alterationseverse to normal after thyroid hormone replacement ther-
py. Future studies are needed to define the underlying
echanisms and clinical importance of these abnormalities
n terms of symptoms, exercise tolerance, and outcome.
cknowledgment
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